These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21126631)

  • 21. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
    Wang M; Weber DM; Delasalle K; Alexanian R
    Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
    Morgan GJ; Schey SA; Wu P; Srikanth M; Phekoo KJ; Jenner M; Davies FE
    Br J Haematol; 2007 May; 137(3):268-9. PubMed ID: 17408469
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
    Rasche L; Einsele H; Nitschmann S
    Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
    [No Abstract]   [Full Text] [Related]  

  • 24. Lenalidomide plus dexamethasone in multiple myeloma.
    Das M
    Lancet Oncol; 2018 Jan; 19(1):e12. PubMed ID: 29175148
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating novel therapies in the transplant paradigm.
    Harousseau JL
    Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
    Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
    Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
    Niesvizky R; Naib T; Christos PJ; Jayabalan D; Furst JR; Jalbrzikowski J; Zafar F; Mark T; Lent R; Pearse RN; Ely S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M
    Br J Haematol; 2007 Sep; 138(5):640-3. PubMed ID: 17686058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients.
    Guglielmelli T; Petrucci MT; Saglio G; Palumbo A
    Br J Haematol; 2011 Jan; 152(1):108-10. PubMed ID: 21083653
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combo drug therapy beneficial for new cases of multiple myeloma.
    Health News; 2006 Feb; 12(2):9. PubMed ID: 16456922
    [No Abstract]   [Full Text] [Related]  

  • 32. Thalidomide with continuous low-dose dexamethasone for multiple myeloma.
    Gardyn J
    J Clin Oncol; 2005 Feb; 23(6):1323. PubMed ID: 15718336
    [No Abstract]   [Full Text] [Related]  

  • 33. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
    van de Donk NW; Wittebol S; Minnema MC; Lokhorst HM
    Br J Haematol; 2010 Jan; 148(2):335-7. PubMed ID: 20085583
    [No Abstract]   [Full Text] [Related]  

  • 34. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of relapsed and relapsed refractory myeloma.
    Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
    Sanchez E; Li M; Li J; Wang C; Chen H; Jones-Bolin S; Hunter K; Ruggeri B; Berenson JR
    Leuk Res; 2012 Nov; 36(11):1422-7. PubMed ID: 22906694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
    Du J; Yuan Z; Zhang C; Fu W; Jiang H; Chen B; Hou J
    Leuk Res; 2010 Nov; 34(11):1453-8. PubMed ID: 20122728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
    Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
    Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.